terazosin has been researched along with Adenoma, Prostatic in 191 studies
Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study aims to assess and compare the effects of carvedilol and terazosin plus enalapril on lower urinary tract symptoms (LUTS), the urine flow, and blood pressure (BP) in patients with moderate hypertension (HTN) and benign prostatic hyperplasia (BPH)." | 9.41 | A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. ( DalirAkbari, N; Farshi, A; Khalili, M; Mahmoudinezhad, M; Zomorrodi, A, 2021) |
| "This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension." | 9.14 | [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. ( Fang, J; Li, YL; Liu, HP; Qin, XH; Xu, XP; Yang, C; Zhang, X, 2009) |
| "Terazosin is an alpha1-selective adrenoceptor blocking agent that has been reported in many clinical trials to be an effective choice for the treatment of benign prostatic hyperplasia (BPH)." | 9.12 | Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. ( Lan, SK; Ou, JH; Tsai, YS; Tzai, TS, 2007) |
| "Finasteride, which inhibits the enzyme 5 alpha-reductase, reduces prostate size and relieves the symptoms of benign prostatic hyperplasia (BPH) in men with enlarged prostates." | 9.11 | Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. ( Doggrell, SA, 2004) |
| "The objective of the present study was to evaluate the efficacy and safety of Prostina, a multi-ingredient herbal formulation in benign prostatic hyperplasia (BPH) in comparison with terazosin." | 9.11 | Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia. ( Biswas, NR; Dogra, PN; Kumar, V; Mani, K; Ravi, AK, 2005) |
| "To review and assess the cardiovascular safety of the alpha1-blocker terazosin when used to treat symptomatic benign prostatic hyperplasia (BPH) in patients taking concurrent antihypertensive medications." | 9.09 | Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. ( Lowe, FC; Olson, PJ; Padley, RJ, 1999) |
| " This result was not significant but suggested a favorable effect of terazosin on diminishing the risk of coronary heart disease." | 9.09 | [Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy]. ( Kageyama, S; Tamaki, M; Ueda, T, 1999) |
| "The objective of this open randomized clinical study was to compare the short-term efficacy and safety of three alpha-1 blockers, prazosin, terazosin and tamsulosin, in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)." | 9.09 | Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. ( Tsujii, T, 2000) |
| "We compared the efficacy of once a day administration of terazosin hydrochloride with that of twice a day administration for benign prostatic hyperplasia (BPH) patients." | 9.09 | [A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin]. ( Ikemoto, I; Ohishi, Y; Ohnishi, T; Suzuki, H; Suzuki, Y; Yamazaki, H, 2001) |
| "To evaluate long-term efficacy and safety of terazosin, a selective alpha 1 blocker, in the treatment of benign prostatic hyperplasia (BPH)." | 9.08 | Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. ( Lepor, H, 1995) |
| "We developed a decision analytic model to compare the costs of treatment for an initial 2-year period with finasteride, terazosin, and transurethral resection of the prostate (TURP) in men with at least moderate symptoms of benign prostatic hyperplasia (BPH)." | 9.08 | Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. ( Chmiel, JJ; Hillman, AL; Lowe, FC; McDaniel, RL, 1995) |
| "To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha(1)-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH)." | 9.08 | The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. ( Deverka, PA; Hillman, AL; Mason, MF; Maurath, CJ; Oesterling, JE; Padley, RJ; Peskin, E; Roehrborn, CG; Schwartz, JS; Willian, MK, 1996) |
| "We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH)." | 9.08 | Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. ( de La Rosette, JJ; de Wildt, MJ; Debruyne, FM; Rosier, FW; van Iersel, MP; Witjes, WP, 1996) |
| "This study was designed to evaluate the safety and efficacy of the selective alpha 1-adrenoceptor blocker terazosin in the treatment of benign prostatic hyperplasia (BPH)." | 9.08 | A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. ( Barkin, J; Beland, G; Boake, RC; Casey, RW; Elhilali, MM; Fradet, Y; Klotz, LH; Orovan, WL; Ramsey, EW; Schick, E; Trachtenberg, J, 1996) |
| "We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia." | 9.08 | The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. ( Barry, MJ; Brawer, MK; Dixon, CM; Gormley, G; Haakenson, C; Lepor, H; Machi, M; Narayan, P; Padley, RJ; Williford, WO, 1996) |
| "To evaluate the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia (BPH)." | 9.08 | The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. ( Debruyne, FM; Fitzpatrick, J; Kirby, R; Kirk, D; Prezioso, D; Witjes, WP, 1996) |
| "2 mg) of tamsulosin, a selective alpha 1A-adrenoreceptor antagonist, with an increasing dose (1-5 mg) of terazosin, a non-selective antagonist, in the treatment of urinary outflow obstruction associated with benign prostatic hyperplasia (BPH) in Korean patients." | 9.08 | Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. ( Lee, C; Lee, E, 1997) |
| "To determine the effects of terazosin on blood pressure and on antihypertensive therapy when used in managing benign prostatic hyperplasia (BPH)." | 9.08 | Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. ( Kirby, RS, 1998) |
| "To examine the clinical usefulness of selective and non-selective alpha 1-adrenoceptor antagonists, we compared a selective (tamsulosin) and non-selective (terazosin) alpha 1-adrenoceptor antagonists in the treatment of Chinese patients with benign prostatic hyperplasia (BPH)." | 9.08 | Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. ( Gu, FL; Guo, YL; Na, YJ, 1998) |
| "To evaluate the efficacy and tolerability of terazosin, a long-acting selective alpha 1-receptor antagonist, in patients with benign prostatic hyperplasia." | 9.07 | Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. ( Adams, G; Brawer, MK; Epstein, H, 1993) |
| "This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 9.07 | Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. ( Lowe, FC, 1994) |
| "Terazosin is safe and effective in treating concomitant hypertension and BPH." | 9.07 | Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial. ( Guthrie, R, 1994) |
| "This randomised, placebo-controlled, double-blind study was performed to evaluate the efficacy and safety of once-a-day terazosin (10 mg/d) in ambulatory patients (n = 57) with benign prostatic hyperplasia (BPH)." | 9.07 | Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. ( Fabricius, PG; Hannaford, JM, 1992) |
| "The purpose of this multicentre, randomised, placebo-controlled, double-blind study was to verify the safety and efficacy of terazosin, an alpha 1 adrenergic blocker, in patients with benign prostatic hyperplasia (BPH)." | 9.07 | Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. ( Di Silverio, F, 1992) |
| "The primary objective of the present interim analysis of an open label study initiated in December 1988 is to provide further insight into the long-term safety, efficacy and compliance of terazosin, a long-acting selective alpha 1-blocker, for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 9.07 | The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Meretyk, S, 1992) |
| "Terazosin, a selective, long-acting alpha 1-adrenergic blocker, was evaluated in 44 men with benign prostatic hyperplasia." | 9.07 | Efficacy of terazosin in patients with benign prostatic hyperplasia. ( Laddu, A; Matzkin, H; Rangel, MC; Soloway, MS, 1992) |
| "This randomized, placebo-controlled, double-blind study was performed to evaluate the efficacy and safety of once-a-day terazosin (10 mg/day) in ambulatory patients (n = 57) with benign prostatic hyperplasia (BPH)." | 9.06 | Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. ( Dunzendorfer, U; Fabricius, PG; Hannaford, JM; Maurath, C; Weizert, P, 1990) |
| "The efficacy and safety of terazosin, a selective long-acting alpha-1-adrenergic blocker, were evaluated in 45 normotensive patients with symptomatic benign prostatic hyperplasia ranging from 50 to 76 years old." | 9.06 | A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Sunshine, H, 1990) |
| "The effectiveness and safety of tamsulosin and terazosin for patients with benign prostatic hyperplasia (BPH) was evaluated by literature review." | 8.85 | Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. ( Chen, W; Dong, Z; Gao, W; Liu, Y; Wang, Z; Yang, K, 2009) |
| "To determine the effectiveness of the long-acting alpha(1)-adrenergic receptor blocking agent terazosin compared with placebo on lower urinary tract symptoms and peak urinary flow rate in men with clinical benign prostatic hyperplasia." | 8.81 | Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. ( Boyle, P; Manski, R; Padley, RJ; Robertson, C; Roehrborn, CG, 2001) |
| "In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia." | 8.79 | Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. ( Lowe, FC; McKiernan, JM, 1997) |
| "This study aimed to explore the effect of terazosin hydrochloride combined with interventional embolisation on prostate volume and quality of life (QOL) of elderly patients with prostatic hyperplasia (PH)." | 8.31 | Effect of Terazosin Hydrochloride Combined with Interventional Embolisation on Prostate Volume and Quality of Life of Elderly Patients with Prostatic Hyperplasia. ( Liu, N; Su, C; Xue, J, 2023) |
| "Terazosin is a selective alpha 1 adrenoceptor antagonist that is currently under clinical investigation for the treatment of clinical BPH." | 7.77 | Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. ( Laddu, A; Lepor, H, 1992) |
| "To investigate the effects of amlodipine, a dihydropyridine calcium-channel blocker, alone or combined with terazosin, on urodynamics in rats with benign prostatic hyperplasia (BPH) and in female rats with detrusor instability (DI)." | 7.75 | Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity. ( Chen, GL; Liu, HP; Liu, P; Xu, XP, 2009) |
| "The objective of this meta-analysis of randomized controlled trials (RCTs) of terazosin versus placebo in men with benign prostatic hyperplasia (BPH) was to evaluate the effect of terazosin on lower urinary tract symptoms." | 7.72 | Effect of terazosin on clinical benign prostatic hyperplasia in older adults. ( Ahmed, A; Mudiyala, R, 2003) |
| "Thirty-six male patients with symptomatic benign prostatic hyperplasia (BPH) with a serum prostate-specific antigen level of 4-10 ng/mL underwent MRI with body coil, transrectal prostate ultrasonography and biopsy prior to terazosin therapy." | 7.71 | Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia. ( Alkibay, T; Ataoglu , O; Atilla, S; Isen, K; Isik, S; Sezer, C; Sinik, Z; Sözen, S, 2001) |
| "We evaluated the short-term efficacy of terazosin for treating symptomatic benign prostatic hyperplasia (BPH)." | 7.71 | The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia. ( Akimoto, M; Horiuchi, K; Suzuki, Y; Tsuboi, N; Yoshida, K, 2001) |
| "To determine the changes in plasma lipid levels in symptomatic benign prostatic hyperplasia (BPH) patients receiving terazosin treatment." | 7.71 | Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia. ( Akbay, E; Bozlu, M; Cayan, S; Doruk, E; Ulusoy, E, 2001) |
| "Recent evidence indicated that an alpha 1 blocker, doxazosin, induces prostate apoptosis in patients with benign prostatic hyperplasia (BPH)." | 7.70 | Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. ( Borkowski, A; Chon, JK; Isaacs, JT; Jacobs, SC; Kyprianou, N; Partin, AW, 1999) |
| "We identified 69 men with symptomatic benign prostatic hyperplasia (BPH) who had been receiving 5 mg/day (n = 33) of finasteride or 2 to 5 mg/day (n = 14) of terazosin or no therapy ("watchful waiting") (n = 22)." | 7.69 | Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. ( Andriole, GL; Catalona, WJ; Keetch, DW; Ratliff, TL, 1997) |
| "The once-daily alpha 1 blocker terazosin was administered to 36 men with symptomatic benign prostatic hyperplasia (BPH) who had previously been scheduled for transurethral resection of the prostate (TURP)." | 7.68 | The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin. ( Woods, AL, 1992) |
| "The efficacy and safety of terazosin was evaluated in 28 normotensive patients with symptomatic benign prostatic hyperplasia (BPH) ranging in age between 52-72 years." | 7.67 | The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Wozniak-Petrofsky, J, 1989) |
| "The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50." | 6.73 | Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. ( Li, HZ; Wang, W; Xiao, H; Yang, Y; Zhang, X; Zhang, Y; Zhao, XF, 2007) |
| "Tamsulosin (0." | 6.69 | A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. ( Hirao, Y; Kamidono, S; Kishimoto, T; Kurita, T; Okada, H; Okajima, E; Okuyama, A; Ozono, S; Park, Y; Yamamoto, K; Yoshioka, T, 2000) |
| "Treatment with terazosin was initiated with 1 mg daily for 3 days, followed by 2 mg daily for 25 days." | 6.68 | The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. ( Auerbach, S; Kaplan, SA; Lloyd, LK; Milam, DE; Oesterling, JE; Padley, RJ; Roehrborn, CG, 1996) |
| "All terazosin treatment groups exhibited significantly greater decreases in total Boyarsky symptom score than the placebo group." | 6.67 | A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. ( Auerbach, S; Leifer, G; Lepor, H; Lowe, F; Madsen, P; Moon, T; Narayan, P; Puras-Baez, A; Soloway, M, 1992) |
| "All terazosin treatment groups showed dramatic improvement in obstructive symptoms when compared with the placebo group, but these differences were not statistically significant because of the small numbers of patients in each group." | 6.67 | Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. ( Buckley, JF; Chilton, CP; Ibrahim, I; Kaisary, AV; Kirk, D; Lloyd, SN, 1992) |
| "Terazosin was shown to have a four hundred-fold greater affinity for alpha-1 binding sites." | 6.66 | Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. ( Baumann, M; Gup, DI; Lepor, H; Shapiro, E, 1988) |
| "Terazosin is an alpha 1 receptor antagonist which has been shown in placebo-controlled trials to significantly improve American Urology Association (AUA) symptom and quality-of-life scores and symptom problem index ('bother' score), as well as increase peak urinary flow rate, in men with BPH." | 6.40 | Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia. ( Goa, KL; Plosker, GL, 1997) |
| "The present study aims to assess and compare the effects of carvedilol and terazosin plus enalapril on lower urinary tract symptoms (LUTS), the urine flow, and blood pressure (BP) in patients with moderate hypertension (HTN) and benign prostatic hyperplasia (BPH)." | 5.41 | A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. ( DalirAkbari, N; Farshi, A; Khalili, M; Mahmoudinezhad, M; Zomorrodi, A, 2021) |
| "In terazosin treated patients, improvement after 3 months were as follows, IPSS 3." | 5.33 | Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. ( Anwarul Islam, AK; Kashem, MA; Kibria, SA; Shameem, IA, 2005) |
| "Medical treatment of benign prostatic hyperplasia (BPH) targets relief of symptoms by causing either relaxation of the prostatic smooth muscle with alpha1 adrenergic blockade, or shrinkage of the gland with 5alpha-reductase inhibitors." | 5.31 | Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. ( Borkowski, A; Chon, JK; Glassman, DT; Jacobs, SC; Kyprianou, N, 2001) |
| "Terazosin treatment, even 2 mg." | 5.31 | Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. ( Furuya, S; Itoh, N; Masumori, N; Ogura, H; Sato, Y; Takahashi, A; Tanaka, Y; Tsukamoto, T, 2002) |
| "This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension." | 5.14 | [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. ( Fang, J; Li, YL; Liu, HP; Qin, XH; Xu, XP; Yang, C; Zhang, X, 2009) |
| "Terazosin is an alpha1-selective adrenoceptor blocking agent that has been reported in many clinical trials to be an effective choice for the treatment of benign prostatic hyperplasia (BPH)." | 5.12 | Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. ( Lan, SK; Ou, JH; Tsai, YS; Tzai, TS, 2007) |
| "Finasteride, which inhibits the enzyme 5 alpha-reductase, reduces prostate size and relieves the symptoms of benign prostatic hyperplasia (BPH) in men with enlarged prostates." | 5.11 | Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. ( Doggrell, SA, 2004) |
| "The objective of the present study was to evaluate the efficacy and safety of Prostina, a multi-ingredient herbal formulation in benign prostatic hyperplasia (BPH) in comparison with terazosin." | 5.11 | Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia. ( Biswas, NR; Dogra, PN; Kumar, V; Mani, K; Ravi, AK, 2005) |
| "To clarify the influence of hypertension on lower urinary tract symptoms (LUTS) we examined the relationship between blood pressure, LUTS, and the effect of terazosin on LUTS in patients with benign prostatic hyperplasia (BPH)." | 5.10 | Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. ( Gakiya, M; Goya, M; Hatano, T; Ikehara, A; Kadekawa, K; Nakayama, T; Nashiro, F; Ogawa, Y; Sugaya, K, 2003) |
| "To review and assess the cardiovascular safety of the alpha1-blocker terazosin when used to treat symptomatic benign prostatic hyperplasia (BPH) in patients taking concurrent antihypertensive medications." | 5.09 | Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications. ( Lowe, FC; Olson, PJ; Padley, RJ, 1999) |
| " This result was not significant but suggested a favorable effect of terazosin on diminishing the risk of coronary heart disease." | 5.09 | [Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy]. ( Kageyama, S; Tamaki, M; Ueda, T, 1999) |
| "The objective of this open randomized clinical study was to compare the short-term efficacy and safety of three alpha-1 blockers, prazosin, terazosin and tamsulosin, in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)." | 5.09 | Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. ( Tsujii, T, 2000) |
| "To evaluate the efficacy and to describe the modalities of use of terazosin hydrochloride dihydrate, prescribed under conditions of routine clinical practice to a vast population of patients with benign prostatic hyperplasia (BPH)." | 5.09 | [Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination]. ( Boumendil, O; Reitz, C; Rossi, D; Serment, G, 2000) |
| "In a randomized, controlled clinical trial, 52 patients with lower urinary tract symptoms due to benign prostatic hyperplasia received terazosin treatment and 51 underwent microwave treatment under topical anesthesia." | 5.09 | Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months. ( Basharkhah, A; Djavan, B; Fakhari, M; Harik, M; Marberger, M; Planz, B; Remzi, M; Roehrborn, CG; Seitz, C; Waldert, M, 2001) |
| "We compared the efficacy of once a day administration of terazosin hydrochloride with that of twice a day administration for benign prostatic hyperplasia (BPH) patients." | 5.09 | [A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin]. ( Ikemoto, I; Ohishi, Y; Ohnishi, T; Suzuki, H; Suzuki, Y; Yamazaki, H, 2001) |
| "To evaluate long-term efficacy and safety of terazosin, a selective alpha 1 blocker, in the treatment of benign prostatic hyperplasia (BPH)." | 5.08 | Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. ( Lepor, H, 1995) |
| "We developed a decision analytic model to compare the costs of treatment for an initial 2-year period with finasteride, terazosin, and transurethral resection of the prostate (TURP) in men with at least moderate symptoms of benign prostatic hyperplasia (BPH)." | 5.08 | Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. ( Chmiel, JJ; Hillman, AL; Lowe, FC; McDaniel, RL, 1995) |
| "To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha(1)-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH)." | 5.08 | The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. ( Deverka, PA; Hillman, AL; Mason, MF; Maurath, CJ; Oesterling, JE; Padley, RJ; Peskin, E; Roehrborn, CG; Schwartz, JS; Willian, MK, 1996) |
| "We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH)." | 5.08 | Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. ( de La Rosette, JJ; de Wildt, MJ; Debruyne, FM; Rosier, FW; van Iersel, MP; Witjes, WP, 1996) |
| "This study was designed to evaluate the safety and efficacy of the selective alpha 1-adrenoceptor blocker terazosin in the treatment of benign prostatic hyperplasia (BPH)." | 5.08 | A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. ( Barkin, J; Beland, G; Boake, RC; Casey, RW; Elhilali, MM; Fradet, Y; Klotz, LH; Orovan, WL; Ramsey, EW; Schick, E; Trachtenberg, J, 1996) |
| "We compared the safety and efficacy of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia." | 5.08 | The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. ( Barry, MJ; Brawer, MK; Dixon, CM; Gormley, G; Haakenson, C; Lepor, H; Machi, M; Narayan, P; Padley, RJ; Williford, WO, 1996) |
| "To evaluate the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia (BPH)." | 5.08 | The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. ( Debruyne, FM; Fitzpatrick, J; Kirby, R; Kirk, D; Prezioso, D; Witjes, WP, 1996) |
| "2 mg) of tamsulosin, a selective alpha 1A-adrenoreceptor antagonist, with an increasing dose (1-5 mg) of terazosin, a non-selective antagonist, in the treatment of urinary outflow obstruction associated with benign prostatic hyperplasia (BPH) in Korean patients." | 5.08 | Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. ( Lee, C; Lee, E, 1997) |
| "A total of 1,229 subjects with clinical benign prostatic hyperplasia (BPH) were randomized to 1 year of placebo, finasteride, terazosin or drug combination." | 5.08 | The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. ( Barry, MJ; Haakenson, C; Jones, K; Lepor, H; Williford, WO, 1998) |
| "To determine the effects of terazosin on blood pressure and on antihypertensive therapy when used in managing benign prostatic hyperplasia (BPH)." | 5.08 | Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. ( Kirby, RS, 1998) |
| "To examine the clinical usefulness of selective and non-selective alpha 1-adrenoceptor antagonists, we compared a selective (tamsulosin) and non-selective (terazosin) alpha 1-adrenoceptor antagonists in the treatment of Chinese patients with benign prostatic hyperplasia (BPH)." | 5.08 | Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. ( Gu, FL; Guo, YL; Na, YJ, 1998) |
| "To evaluate the efficacy and tolerability of terazosin, a long-acting selective alpha 1-receptor antagonist, in patients with benign prostatic hyperplasia." | 5.07 | Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. ( Adams, G; Brawer, MK; Epstein, H, 1993) |
| "The purpose of this trial was to study the use of terazosin in nonbacterial prostatitis/prostatodynia, and to evaluate a new symptom score sheet for this disease." | 5.07 | Use of terazosin in prostatodynia and validation of a symptom score questionnaire. ( Moon, TD; Neal, DE, 1994) |
| "This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 5.07 | Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. ( Lowe, FC, 1994) |
| "Terazosin is safe and effective in treating concomitant hypertension and BPH." | 5.07 | Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial. ( Guthrie, R, 1994) |
| "This randomised, placebo-controlled, double-blind study was performed to evaluate the efficacy and safety of once-a-day terazosin (10 mg/d) in ambulatory patients (n = 57) with benign prostatic hyperplasia (BPH)." | 5.07 | Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up. ( Fabricius, PG; Hannaford, JM, 1992) |
| "The purpose of this multicentre, randomised, placebo-controlled, double-blind study was to verify the safety and efficacy of terazosin, an alpha 1 adrenergic blocker, in patients with benign prostatic hyperplasia (BPH)." | 5.07 | Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. ( Di Silverio, F, 1992) |
| "The primary objective of the present interim analysis of an open label study initiated in December 1988 is to provide further insight into the long-term safety, efficacy and compliance of terazosin, a long-acting selective alpha 1-blocker, for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 5.07 | The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Meretyk, S, 1992) |
| "Terazosin, a selective, long-acting alpha 1-adrenergic blocker, was evaluated in 44 men with benign prostatic hyperplasia." | 5.07 | Efficacy of terazosin in patients with benign prostatic hyperplasia. ( Laddu, A; Matzkin, H; Rangel, MC; Soloway, MS, 1992) |
| "This randomized, placebo-controlled, double-blind study was performed to evaluate the efficacy and safety of once-a-day terazosin (10 mg/day) in ambulatory patients (n = 57) with benign prostatic hyperplasia (BPH)." | 5.06 | Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. ( Dunzendorfer, U; Fabricius, PG; Hannaford, JM; Maurath, C; Weizert, P, 1990) |
| "The efficacy and safety of terazosin, a selective long-acting alpha-1-adrenergic blocker, were evaluated in 45 normotensive patients with symptomatic benign prostatic hyperplasia ranging from 50 to 76 years old." | 5.06 | A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Sunshine, H, 1990) |
| "The effectiveness and safety of tamsulosin and terazosin for patients with benign prostatic hyperplasia (BPH) was evaluated by literature review." | 4.85 | Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. ( Chen, W; Dong, Z; Gao, W; Liu, Y; Wang, Z; Yang, K, 2009) |
| "To determine the effectiveness of the long-acting alpha(1)-adrenergic receptor blocking agent terazosin compared with placebo on lower urinary tract symptoms and peak urinary flow rate in men with clinical benign prostatic hyperplasia." | 4.81 | Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. ( Boyle, P; Manski, R; Padley, RJ; Robertson, C; Roehrborn, CG, 2001) |
| "In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia." | 4.79 | Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. ( Lowe, FC; McKiernan, JM, 1997) |
| "This study aimed to explore the effect of terazosin hydrochloride combined with interventional embolisation on prostate volume and quality of life (QOL) of elderly patients with prostatic hyperplasia (PH)." | 4.31 | Effect of Terazosin Hydrochloride Combined with Interventional Embolisation on Prostate Volume and Quality of Life of Elderly Patients with Prostatic Hyperplasia. ( Liu, N; Su, C; Xue, J, 2023) |
| "Terazosin is a selective alpha 1 adrenoceptor antagonist that is currently under clinical investigation for the treatment of clinical BPH." | 3.77 | Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. ( Laddu, A; Lepor, H, 1992) |
| " The present review of terazosin in males with symptomatic BPH supports the following conclusions: (1) the dose of terazosin can be safely titrated to 10 mg in normotensive and hypertensive patients with symptomatic BPH; (2) the adverse events associated with doses of terazosin up to 10 mg are relatively mild and reversible; and (3) the improvements in the outcome parameters (symptom scores and urinary flow rates) are clinically and statistically significant." | 3.77 | The efficacy and safety of terazosin for the treatment of symptomatic BPH. ( Henry, D; Laddu, AR; Lepor, H, 1991) |
| " The validity and reliability were assessed in 76 patients with urinary symptoms due to benign prostatic hyperplasia (BPH) and in 63 control subjects without BPH; 25 patients had transurethral resection of prostate (TURP) whereas the remaining 51 patients were treated with terazosin." | 3.76 | Development and validation of an Arabic version of the International Prostate Symptom Score. ( Hammad, FT; Kaya, MA, 2010) |
| "To investigate the effects of amlodipine, a dihydropyridine calcium-channel blocker, alone or combined with terazosin, on urodynamics in rats with benign prostatic hyperplasia (BPH) and in female rats with detrusor instability (DI)." | 3.75 | Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity. ( Chen, GL; Liu, HP; Liu, P; Xu, XP, 2009) |
| "The objective of this meta-analysis of randomized controlled trials (RCTs) of terazosin versus placebo in men with benign prostatic hyperplasia (BPH) was to evaluate the effect of terazosin on lower urinary tract symptoms." | 3.72 | Effect of terazosin on clinical benign prostatic hyperplasia in older adults. ( Ahmed, A; Mudiyala, R, 2003) |
| "Thirty-six male patients with symptomatic benign prostatic hyperplasia (BPH) with a serum prostate-specific antigen level of 4-10 ng/mL underwent MRI with body coil, transrectal prostate ultrasonography and biopsy prior to terazosin therapy." | 3.71 | Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia. ( Alkibay, T; Ataoglu , O; Atilla, S; Isen, K; Isik, S; Sezer, C; Sinik, Z; Sözen, S, 2001) |
| "We evaluated the short-term efficacy of terazosin for treating symptomatic benign prostatic hyperplasia (BPH)." | 3.71 | The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia. ( Akimoto, M; Horiuchi, K; Suzuki, Y; Tsuboi, N; Yoshida, K, 2001) |
| "Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation." | 3.71 | Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001) |
| "A total of 34 men with benign prostatic hyperplasia (BPH) who have been on terazosin treatment (for the obstructive symptoms) were pathologically diagnosed with prostate cancer following surgery." | 3.71 | Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. ( Borkowski, A; Isaacs, JT; Jacobs, SC; Keledjian, K; Kim, G; Kyprianou, N, 2001) |
| "To determine the changes in plasma lipid levels in symptomatic benign prostatic hyperplasia (BPH) patients receiving terazosin treatment." | 3.71 | Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia. ( Akbay, E; Bozlu, M; Cayan, S; Doruk, E; Ulusoy, E, 2001) |
| "alpha(1) Adrenergic receptors mediate both vascular and lower urinary tract tone, and alpha(1) receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH)." | 3.70 | In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia. ( Barrish, A; Barrow, JC; Broten, TP; Chang, RS; Ellis, JD; Forray, C; Freidinger, RM; Gilbert, KF; Glass, KL; Homnick, CF; Kassahun, K; Kling, P; Leppert, P; Nagarathnam, D; Nantermet, PG; O'Malley, SS; Olah, TV; Ransom, RW; Reiss, D; Rittle, KE; Schorn, TW; Selnick, HG; Steele, TG, 2000) |
| "Recent evidence indicated that an alpha 1 blocker, doxazosin, induces prostate apoptosis in patients with benign prostatic hyperplasia (BPH)." | 3.70 | Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. ( Borkowski, A; Chon, JK; Isaacs, JT; Jacobs, SC; Kyprianou, N; Partin, AW, 1999) |
| "We identified 69 men with symptomatic benign prostatic hyperplasia (BPH) who had been receiving 5 mg/day (n = 33) of finasteride or 2 to 5 mg/day (n = 14) of terazosin or no therapy ("watchful waiting") (n = 22)." | 3.69 | Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. ( Andriole, GL; Catalona, WJ; Keetch, DW; Ratliff, TL, 1997) |
| "To determine the safety and efficacy of alpha blockade with doxazosin and terazosin in men over the age of 80 years with symptomatic benign prostatic hyperplasia (BPH)." | 3.69 | The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years. ( Ikeguchi, E; Kaplan, SA; Santarosa, RP; Te, AE, 1997) |
| "The adrenergic alpha-1 and -2 adrenoceptors in six human hypertrophied prostatic adenomas were measured in the saturation experiment using 3H-prazosin and 3H-yohimbine." | 3.68 | [Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas]. ( Kondo, S; Morita, T, 1992) |
| "The once-daily alpha 1 blocker terazosin was administered to 36 men with symptomatic benign prostatic hyperplasia (BPH) who had previously been scheduled for transurethral resection of the prostate (TURP)." | 3.68 | The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin. ( Woods, AL, 1992) |
| "The adrenergic alpha-1 and -2 adrenoceptors in human hypertrophied and non-hypertrophied prostatic adenomas were measured in the saturation experiment using 3H-prazosin and 3H-yohimbine." | 3.68 | [Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity]. ( Morita, T, 1991) |
| "Clinical trials are currently underway to evaluate the efficacy of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH)." | 3.67 | The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain. ( Baumann, M; Lepor, H; Shapiro, E, 1988) |
| "The efficacy and safety of terazosin was evaluated in 28 normotensive patients with symptomatic benign prostatic hyperplasia (BPH) ranging in age between 52-72 years." | 3.67 | The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia. ( Knapp-Maloney, G; Lepor, H; Wozniak-Petrofsky, J, 1989) |
| "The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50." | 2.73 | Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. ( Li, HZ; Wang, W; Xiao, H; Yang, Y; Zhang, X; Zhang, Y; Zhao, XF, 2007) |
| " No unknown adverse reactions were observed in either groups, and the drugs were shown to be highly safe." | 2.70 | [The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy]. ( Fujioka, T; Goto, Y; Isurugi, K; Katoh, T; Numasato, S; Obara, W; Omori, S; Suzuki, Y, 2001) |
| "Once-daily dosing of TAM after breakfast at a fixed dose level (0." | 2.69 | A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. ( de Mey, C; McEwen, J; Michel, MC; Moreland, T, 1998) |
| "Medical management of benign prostatic hyperplasia (BPH) giving rise to lower urinary tract symptomatology (LUTS) has emerged as the mainstay for first-line therapy." | 2.69 | Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. ( Brawer, MK; Jones, K; Lepor, H; Lin, DW; Williford, WO, 1999) |
| "We determined the mechanism of adverse events associated with alpha1-blockers for treating benign prostatic hyperplasia (BPH)." | 2.69 | The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. ( Jones, K; Lepor, H; Williford, W, 2000) |
| "Tamsulosin (0." | 2.69 | A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. ( Hirao, Y; Kamidono, S; Kishimoto, T; Kurita, T; Okada, H; Okajima, E; Okuyama, A; Ozono, S; Park, Y; Yamamoto, K; Yoshioka, T, 2000) |
| " Parameters evaluated included Boyarsky symptom score (Sx), peak uroflow (Qmax), blood pressure and occurrence of adverse events." | 2.68 | Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety. ( Kaplan, SA; Olsson, CA; Soldo, KA, 1995) |
| "Treatment with terazosin was initiated with 1 mg daily for 3 days, followed by 2 mg daily for 25 days." | 2.68 | The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. ( Auerbach, S; Kaplan, SA; Lloyd, LK; Milam, DE; Oesterling, JE; Padley, RJ; Roehrborn, CG, 1996) |
| "Terazosin treatment resulted in significant changes in flow rate and residual urine, however, changes in flow rates were not influenced by prostate size, while a marked decrease in residual urine was found in patients with large prostates." | 2.68 | Influence of prostate size on terazosin efficacy. ( Becopoulos, T; Christofis, I; Mitropoulos, D, 1997) |
| "All terazosin treatment groups exhibited significantly greater decreases in total Boyarsky symptom score than the placebo group." | 2.67 | A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. ( Auerbach, S; Leifer, G; Lepor, H; Lowe, F; Madsen, P; Moon, T; Narayan, P; Puras-Baez, A; Soloway, M, 1992) |
| "All terazosin treatment groups showed dramatic improvement in obstructive symptoms when compared with the placebo group, but these differences were not statistically significant because of the small numbers of patients in each group." | 2.67 | Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. ( Buckley, JF; Chilton, CP; Ibrahim, I; Kaisary, AV; Kirk, D; Lloyd, SN, 1992) |
| "Terazosin is an alpha-1 adrenergic blocking agent currently marketed as an antihypertensive." | 2.66 | Clinical experience: symptomatic management of BPH with terazosin. ( Dunzendorfer, U, 1988) |
| "Terazosin was shown to have a four hundred-fold greater affinity for alpha-1 binding sites." | 2.66 | Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. ( Baumann, M; Gup, DI; Lepor, H; Shapiro, E, 1988) |
| "Medical treatment for benign prostatic hyperplasia is reviewed by the author." | 2.42 | [Pharmacologic treatment of benign prostatic hyperplasia]. ( Romics, I, 2003) |
| "All published data on benign prostatic hyperplasia in Saudi Arabia was reviewed." | 2.41 | Benign prostatic hyperplasia. The Saudi perspective in the year 2000. ( Atwa, MA; Mahassini, SH; Mosli, HA, 2000) |
| "Men with moderate symptoms of benign prostatic hyperplasia (BPH) are the best candidates for medical treatment, while surgery is usually indicated for patients with severe symptoms." | 2.40 | Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. ( Eri, LM; Tveter, KJ, 1997) |
| "Terazosin is an alpha 1 receptor antagonist which has been shown in placebo-controlled trials to significantly improve American Urology Association (AUA) symptom and quality-of-life scores and symptom problem index ('bother' score), as well as increase peak urinary flow rate, in men with BPH." | 2.40 | Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia. ( Goa, KL; Plosker, GL, 1997) |
| "dizziness and orthostatic hypotension)." | 2.40 | A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. ( Djavan, B; Marberger, M, 1999) |
| "Symptomatic benign prostatic hyperplasia (BPH) is a common condition in older men and has a significant impact on their daily lives." | 2.39 | Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. ( Chapple, CR, 1996) |
| "Since trial results for benign prostatic hyperplasia phytotherapeutic agents are inconsistent, they may also be contaminated." | 1.36 | Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. ( Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA, 2010) |
| "Forty males with benign prostatic hyperplasia (BPH) applying to the Department of Urology with lower urinary tract symptoms (LUTS) were enrolled in the study consecutively." | 1.35 | Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals. ( Adayener, C; Akyol, I; Ates, F; Iseri, C; Senkul, T; Yilmaz, O, 2008) |
| "Treatment with terazosin can reduce patients' episodes of nocturia both subjectively and objectively in some men with LUTS." | 1.33 | alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction. ( Kim, SW; Ku, JH; Paick, JS; Shin, JW; Yang, JH, 2006) |
| "In terazosin treated patients, improvement after 3 months were as follows, IPSS 3." | 1.33 | Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. ( Anwarul Islam, AK; Kashem, MA; Kibria, SA; Shameem, IA, 2005) |
| "Men participating in the 2001 and 2002 Prostate Cancer Awareness Week screening for prostate cancer were given a self-administered questionnaire." | 1.32 | Herbal and vitamin supplement use in a prostate cancer screening population. ( Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C, 2004) |
| "Benign prostate hyperplasia (BPH) and prostate cancer established that disruption of the molecular mechanisms that regulate apoptosis and cell proliferation among the stromal and epithelial cell populations, may underlie the neoplastic development that characterizes the aging gland." | 1.31 | Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. ( Benning, CM; Chon, J; Kyprianou, N, 2000) |
| "Medical treatment of benign prostatic hyperplasia (BPH) targets relief of symptoms by causing either relaxation of the prostatic smooth muscle with alpha1 adrenergic blockade, or shrinkage of the gland with 5alpha-reductase inhibitors." | 1.31 | Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. ( Borkowski, A; Chon, JK; Glassman, DT; Jacobs, SC; Kyprianou, N, 2001) |
| "Tamsulosin has a markedly lower re-treatment percentage than alfuzosin and terazosin." | 1.31 | Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. ( de la Rosette, JJ; Floratos, DL; Kiemeney, LA; Kortmann, BB; Rossi, C; Sonke, GS, 2002) |
| "Terazosin treatment, even 2 mg." | 1.31 | Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. ( Furuya, S; Itoh, N; Masumori, N; Ogura, H; Sato, Y; Takahashi, A; Tanaka, Y; Tsukamoto, T, 2002) |
| "In patients without bladder outlet obstruction (BOO), improvement in maximum flow and symptom scores with little change in the degree of obstruction was most apparent, whereas a decrease of detrusor pressure at maximum flow was observed mainly in patients with BOO." | 1.30 | Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. ( de la Rosette, JJ; Debruyne, FM; Neal, DE; Robertson, A; Rosier, PF; Witjes, WP, 1997) |
| "The purpose of this study was to determine the potency and selectivity of the alpha-1 adrenergic receptor antagonist terazosin based on relationships between plasma concentrations and blockade of intraurethral pressure (IUP) and mean arterial pressure (MAP) responses after single dosing and to determine cumulative effects after repeated dosing." | 1.30 | Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin. ( Brune, ME; Hancock, AA; Katwala, SP; Kerwin, JF; Milicic, I; Witte, DG, 1997) |
| " Dosage was started at 1 mg/d and increased as tolerated to 2, 5, and 10 mg/d over the test period." | 1.29 | Effect of terazosin on urine storage and voiding in the aging male with prostatism. ( Bottaccini, MR; Gleason, DM, 1994) |
| "Benign prostatic hypertrophy provokes clinical manifestations correlated on one hand to a static obstructive component, due to the increase in glandular size, and on the other hand to a dynamic component, controlled by the alpha adrenergic autonomic system which gives the smooth muscular tonus of the prostatic adenoma." | 1.29 | [Terazosin in the treatment of benign prostatic hypertrophy]. ( Andres, M; Carmignani, L; De Cobelli, O; Kocjancic, E; Musci, R; Panizzutti, M; Rocco, F, 1995) |
| "Medical management of benign prostatic hyperplasia (BPH) is an alternative to surgical treatment of this disease." | 1.29 | Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. ( Breslin, D; Chou, TC; Felsen, D; Fields, DW; Kane, M; Marion, DN; Vaughan, ED, 1993) |
| " The daily dosage of terazosin was titrated to 5 mg over a 2-week interval." | 1.28 | The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. ( Lepor, H; Machi, G, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (2.62) | 18.7374 |
| 1990's | 96 (50.26) | 18.2507 |
| 2000's | 74 (38.74) | 29.6817 |
| 2010's | 14 (7.33) | 24.3611 |
| 2020's | 2 (1.05) | 2.80 |
| Authors | Studies |
|---|---|
| Kenny, B | 1 |
| Ballard, S | 1 |
| Blagg, J | 1 |
| Fox, D | 1 |
| Elworthy, TR | 1 |
| Ford, AP | 1 |
| Bantle, GW | 1 |
| Morgans, DJ | 1 |
| Ozer, RS | 1 |
| Palmer, WS | 1 |
| Repke, DB | 1 |
| Romero, M | 1 |
| Sandoval, L | 1 |
| Sjogren, EB | 1 |
| Talamás, FX | 1 |
| Vazquez, A | 1 |
| Wu, H | 1 |
| Arredondo, NF | 1 |
| Blue, DR | 1 |
| DeSousa, A | 1 |
| Gross, LM | 1 |
| Kava, MS | 1 |
| Lesnick, JD | 1 |
| Vimont, RL | 1 |
| Williams, TJ | 1 |
| Zhu, QM | 1 |
| Pfister, JR | 1 |
| Clarke, DE | 1 |
| Meyer, MD | 3 |
| Altenbach, RJ | 3 |
| Basha, FZ | 3 |
| Carroll, WA | 3 |
| Drizin, I | 3 |
| Elmore, SW | 2 |
| Ehrlich, PP | 1 |
| Lebold, SA | 2 |
| Tietje, K | 3 |
| Sippy, KB | 3 |
| Wendt, MD | 3 |
| Plata, DJ | 1 |
| Plagge, F | 1 |
| Buckner, SA | 4 |
| Brune, ME | 5 |
| Hancock, AA | 5 |
| Kerwin, JF | 5 |
| Wong, WC | 1 |
| Chiu, G | 1 |
| Wetzel, JM | 1 |
| Marzabadi, MR | 1 |
| Nagarathnam, D | 2 |
| Wang, D | 1 |
| Fang, J | 2 |
| Miao, SW | 1 |
| Hong, X | 1 |
| Forray, C | 2 |
| Vaysse, PJ | 1 |
| Branchek, TA | 1 |
| Gluchowski, C | 1 |
| Tang, R | 1 |
| Lepor, H | 21 |
| Condon, S | 1 |
| Barrow, JC | 1 |
| Nantermet, PG | 1 |
| Selnick, HG | 1 |
| Glass, KL | 1 |
| Rittle, KE | 1 |
| Gilbert, KF | 1 |
| Steele, TG | 1 |
| Homnick, CF | 1 |
| Freidinger, RM | 1 |
| Ransom, RW | 1 |
| Kling, P | 1 |
| Reiss, D | 1 |
| Broten, TP | 1 |
| Schorn, TW | 1 |
| Chang, RS | 1 |
| O'Malley, SS | 1 |
| Olah, TV | 1 |
| Ellis, JD | 1 |
| Barrish, A | 1 |
| Kassahun, K | 1 |
| Leppert, P | 1 |
| Bai, H | 1 |
| Lee, E | 2 |
| Pratt, JK | 1 |
| Xue, J | 1 |
| Liu, N | 1 |
| Su, C | 1 |
| Ohyama, K | 1 |
| Hori, Y | 1 |
| Sugiura, M | 1 |
| Farshi, A | 1 |
| DalirAkbari, N | 1 |
| Zomorrodi, A | 1 |
| Khalili, M | 1 |
| Mahmoudinezhad, M | 1 |
| Nadeem, HMR | 1 |
| Mohiuddin, E | 1 |
| UdDin, S | 1 |
| Daniyal, M | 1 |
| Usmanghani, K | 1 |
| Sun, JM | 1 |
| Liu, P | 2 |
| Han, WJ | 1 |
| Araki, T | 1 |
| Monden, K | 1 |
| Araki, M | 1 |
| Sosnovskiĭ, SO | 1 |
| Kheĭfets, VKh | 1 |
| Kagan, OF | 1 |
| Barkin, J | 2 |
| Diles, D | 1 |
| Franks, B | 1 |
| Berner, T | 1 |
| Zhang, Y | 2 |
| Shamie, N | 1 |
| Daneshmand, S | 1 |
| Belayneh, M | 1 |
| Korownyk, C | 1 |
| Mamalis, N | 1 |
| Paick, JS | 3 |
| Cho, MC | 1 |
| Song, SH | 1 |
| Kim, SW | 2 |
| Ku, JH | 4 |
| Bar-Yosef, Y | 1 |
| Mabjeesh, NJ | 1 |
| Laufer, M | 1 |
| Neulander, EZ | 1 |
| Kaver, I | 1 |
| Matzkin, H | 2 |
| Yang, T | 1 |
| Zhang, XQ | 1 |
| Feng, YW | 1 |
| Vaughan, CP | 1 |
| Endeshaw, Y | 1 |
| Nagamia, Z | 1 |
| Ouslander, JG | 1 |
| Johnson, TM | 2 |
| Prata, TS | 1 |
| Palmiero, PM | 1 |
| Angelilli, A | 1 |
| Sbeity, Z | 1 |
| De Moraes, CG | 1 |
| Liebmann, JM | 1 |
| Ritch, R | 1 |
| Liu, HP | 2 |
| Chen, GL | 1 |
| Xu, XP | 2 |
| Yang, C | 1 |
| Li, YL | 1 |
| Zhang, X | 2 |
| Qin, XH | 1 |
| Hammad, FT | 1 |
| Kaya, MA | 1 |
| Dong, Z | 1 |
| Wang, Z | 1 |
| Yang, K | 1 |
| Liu, Y | 1 |
| Gao, W | 1 |
| Chen, W | 1 |
| Li, S | 1 |
| Lu, A | 1 |
| Wang, Y | 1 |
| Elterman, DS | 1 |
| Lawrentschuk, N | 1 |
| Guns, E | 1 |
| Hersey, K | 1 |
| Adomat, H | 1 |
| Wood, CA | 1 |
| Fleshner, N | 1 |
| Alan, C | 1 |
| Kırılmaz, B | 1 |
| Koçoğlu, H | 1 |
| Ersay, AR | 1 |
| Ertung, Y | 1 |
| Eren, AE | 1 |
| Krome, S | 1 |
| Sherman, JJ | 1 |
| Welch, RW | 1 |
| Hill, TM | 1 |
| McEwen, C | 1 |
| Erdoğru, T | 1 |
| Ciftcioglu, MA | 1 |
| Emreoglu, I | 1 |
| Usta, MF | 1 |
| Koksal, T | 1 |
| Ozbilim, G | 1 |
| Gulkesen, KH | 1 |
| Baykara, M | 1 |
| Wilt, TJ | 1 |
| Howe, RW | 1 |
| Rutks, IR | 1 |
| MacDonald, R | 1 |
| Mudiyala, R | 1 |
| Ahmed, A | 1 |
| Kyprianou, N | 7 |
| Jones, K | 4 |
| Williford, WO | 4 |
| Kutner, MH | 1 |
| Issa, MM | 1 |
| Gonzalez, CM | 1 |
| McVary, KT | 1 |
| Romics, I | 1 |
| Sugaya, K | 1 |
| Kadekawa, K | 1 |
| Ikehara, A | 1 |
| Nakayama, T | 1 |
| Gakiya, M | 1 |
| Nashiro, F | 1 |
| Goya, M | 1 |
| Hatano, T | 1 |
| Ogawa, Y | 1 |
| Barqawi, A | 1 |
| Gamito, E | 1 |
| O'Donnell, C | 1 |
| Crawford, ED | 2 |
| Tahmatzopoulos, A | 1 |
| Brown, GA | 1 |
| Sussman, DO | 1 |
| Deng, CH | 1 |
| Chen, HR | 1 |
| Qiu, SP | 2 |
| Liu, JZ | 1 |
| Zheng, KL | 1 |
| Mei, H | 1 |
| Doggrell, SA | 1 |
| Kirby, R | 2 |
| Samli, MM | 1 |
| Dincel, C | 1 |
| Bozlu, M | 2 |
| Ulusoy, E | 2 |
| Cayan, S | 2 |
| Akbay, E | 4 |
| Görür, S | 1 |
| Pawar, A | 1 |
| Fahim, M | 1 |
| Dogra, PN | 1 |
| Biswas, NR | 1 |
| Ravi, AK | 1 |
| Mani, K | 1 |
| Kumar, V | 1 |
| O'Leary, MP | 1 |
| Shin, JW | 2 |
| Yang, JH | 2 |
| Um, JM | 1 |
| Anwarul Islam, AK | 1 |
| Kashem, MA | 1 |
| Shameem, IA | 1 |
| Kibria, SA | 1 |
| Yang, Y | 1 |
| Zhao, XF | 1 |
| Li, HZ | 1 |
| Wang, W | 1 |
| Xiao, H | 1 |
| Song, YS | 2 |
| Tsai, YS | 1 |
| Lan, SK | 1 |
| Ou, JH | 1 |
| Tzai, TS | 1 |
| Yang, MG | 1 |
| Zhao, XK | 1 |
| Li, NC | 1 |
| Wu, SL | 1 |
| Jin, J | 1 |
| Kong, CZ | 1 |
| Ye, ZQ | 1 |
| Sun, G | 1 |
| Sun, YH | 1 |
| Sun, YC | 1 |
| Wang, XF | 1 |
| Na, YQ | 1 |
| Koh, MJ | 1 |
| Seah, PP | 1 |
| Tay, YK | 1 |
| Mancer, K | 1 |
| Senkul, T | 1 |
| Yilmaz, O | 1 |
| Iseri, C | 1 |
| Adayener, C | 1 |
| Akyol, I | 1 |
| Ates, F | 1 |
| Seak, CJ | 1 |
| Lin, CC | 1 |
| Rich, KT | 1 |
| Safranek, S | 1 |
| Konen, JC | 1 |
| Brawer, MK | 4 |
| Adams, G | 1 |
| Epstein, H | 1 |
| Neal, DE | 2 |
| Moon, TD | 1 |
| Gleason, DM | 1 |
| Bottaccini, MR | 1 |
| Caine, M | 1 |
| Lowe, FC | 5 |
| Guthrie, R | 1 |
| Larosa, M | 1 |
| Ferretti, S | 1 |
| Salsi, P | 1 |
| Simonazzi, M | 1 |
| Jerant, AF | 1 |
| Stockamp, K | 1 |
| Geller, J | 1 |
| Kirchenbaum, A | 1 |
| Levine, AC | 1 |
| Andres, M | 1 |
| De Cobelli, O | 1 |
| Carmignani, L | 1 |
| Musci, R | 1 |
| Kocjancic, E | 1 |
| Panizzutti, M | 1 |
| Rocco, F | 1 |
| Moon, L | 1 |
| Pfettscher, S | 1 |
| Bartek, JK | 1 |
| McNamee, M | 1 |
| Kreder, KJ | 2 |
| McDaniel, RL | 1 |
| Chmiel, JJ | 1 |
| Hillman, AL | 2 |
| Breslin, D | 1 |
| Fields, DW | 1 |
| Chou, TC | 1 |
| Marion, DN | 1 |
| Kane, M | 1 |
| Vaughan, ED | 1 |
| Felsen, D | 1 |
| Ramsey, EW | 2 |
| Kaplan, SA | 4 |
| Soldo, KA | 1 |
| Olsson, CA | 1 |
| Scheen, AJ | 1 |
| Roehrborn, CG | 7 |
| Oesterling, JE | 4 |
| Auerbach, S | 2 |
| Lloyd, LK | 1 |
| Milam, DE | 1 |
| Padley, RJ | 6 |
| Schwartz, JS | 1 |
| Willian, MK | 1 |
| Peskin, E | 1 |
| Mason, MF | 1 |
| Maurath, CJ | 1 |
| Deverka, PA | 1 |
| Witjes, WP | 4 |
| Rosier, FW | 1 |
| de Wildt, MJ | 1 |
| van Iersel, MP | 1 |
| Debruyne, FM | 4 |
| de La Rosette, JJ | 5 |
| Elhilali, MM | 1 |
| Casey, RW | 1 |
| Boake, RC | 1 |
| Beland, G | 1 |
| Fradet, Y | 1 |
| Trachtenberg, J | 1 |
| Orovan, WL | 1 |
| Schick, E | 1 |
| Klotz, LH | 1 |
| Chapple, CR | 2 |
| Walsh, PC | 1 |
| Barry, MJ | 2 |
| Dixon, CM | 1 |
| Gormley, G | 1 |
| Haakenson, C | 2 |
| Machi, M | 1 |
| Narayan, P | 2 |
| Fitzpatrick, J | 2 |
| Kirk, D | 2 |
| Prezioso, D | 1 |
| Zacks, M | 1 |
| Kuchel, GA | 1 |
| DuBeau, CE | 1 |
| Resnick, NM | 1 |
| Thien, T | 1 |
| Lenders, JW | 1 |
| Frankel, S | 1 |
| Katwala, SP | 2 |
| Milicic, I | 2 |
| Ireland, LM | 1 |
| Rosier, PF | 2 |
| Caris, CT | 1 |
| Eri, LM | 1 |
| Tveter, KJ | 1 |
| Nieder, A | 1 |
| Feser, J | 1 |
| O'Connell, C | 1 |
| Dixon, C | 1 |
| McKiernan, JM | 1 |
| Sperandeo, M | 1 |
| Sperandeo, G | 1 |
| Carella, M | 1 |
| Bianco, G | 1 |
| Cera, A | 1 |
| Scarale, MG | 1 |
| Viola, M | 1 |
| Evans, MF | 1 |
| Frank, J | 1 |
| Robertson, A | 1 |
| Becopoulos, T | 1 |
| Mitropoulos, D | 1 |
| Christofis, I | 1 |
| Witte, DG | 1 |
| Gómez Sancha, F | 1 |
| Fernández Arjona, M | 1 |
| Peinado Ibarra, F | 1 |
| Fernández Borrell, A | 1 |
| Mínguez Martínez, R | 1 |
| Pereira Sanz, I | 1 |
| Olson, PJ | 2 |
| Lee, C | 1 |
| Trinkler, FB | 1 |
| Keetch, DW | 1 |
| Andriole, GL | 1 |
| Ratliff, TL | 1 |
| Catalona, WJ | 1 |
| Te, AE | 1 |
| Ikeguchi, E | 1 |
| Santarosa, RP | 1 |
| Schäfers, RF | 1 |
| Michel, MC | 2 |
| Suzuki, H | 2 |
| Beduschi, MC | 1 |
| Beduschi, R | 1 |
| de Mey, C | 1 |
| McEwen, J | 1 |
| Moreland, T | 1 |
| Hernández-Cano, N | 1 |
| Herranz, P | 1 |
| Lázaro, TE | 1 |
| Mayor, M | 1 |
| Casado, M | 1 |
| Kirby, RS | 1 |
| Djavan, B | 3 |
| Shariat, S | 1 |
| Ghawidel, K | 1 |
| Marberger, M | 3 |
| Plosker, GL | 1 |
| Goa, KL | 1 |
| Chon, JK | 2 |
| Borkowski, A | 3 |
| Partin, AW | 1 |
| Isaacs, JT | 2 |
| Jacobs, SC | 4 |
| Lin, DW | 1 |
| Albertsen, PC | 1 |
| Pellissier, JM | 1 |
| Girman, CJ | 1 |
| Na, YJ | 1 |
| Guo, YL | 1 |
| Gu, FL | 1 |
| Lee, TH | 1 |
| Tamaki, M | 1 |
| Ueda, T | 1 |
| Kageyama, S | 1 |
| Jansen, DJ | 1 |
| Resch, ND | 1 |
| Hoffman, RM | 1 |
| Williford, W | 1 |
| Cerrato, PL | 1 |
| Okada, H | 1 |
| Kamidono, S | 1 |
| Yoshioka, T | 1 |
| Okuyama, A | 1 |
| Ozono, S | 1 |
| Hirao, Y | 1 |
| Okajima, E | 1 |
| Yamamoto, K | 1 |
| Kishimoto, T | 1 |
| Park, Y | 1 |
| Kurita, T | 2 |
| Tsujii, T | 1 |
| Fourcade, RO | 1 |
| Serment, G | 1 |
| Rossi, D | 1 |
| Reitz, C | 1 |
| Boumendil, O | 1 |
| Clifford, GM | 1 |
| Farmer, RD | 2 |
| Bartsch, G | 1 |
| Habib, FK | 1 |
| Ross, M | 1 |
| Bayne, CW | 1 |
| Chon, J | 1 |
| Benning, CM | 1 |
| Caprino, L | 1 |
| Blanchard, K | 1 |
| Hananel, A | 1 |
| Rutchik, S | 1 |
| Sullivan, J | 1 |
| Seitz, C | 1 |
| Remzi, M | 1 |
| Fakhari, M | 1 |
| Waldert, M | 1 |
| Basharkhah, A | 1 |
| Planz, B | 1 |
| Harik, M | 1 |
| Glassman, DT | 1 |
| Suzuki, Y | 3 |
| Katoh, T | 1 |
| Isurugi, K | 1 |
| Obara, W | 1 |
| Omori, S | 1 |
| Goto, Y | 1 |
| Fujioka, T | 1 |
| Numasato, S | 1 |
| Isen, K | 1 |
| Sinik, Z | 1 |
| Alkibay, T | 1 |
| Sezer, C | 1 |
| Sözen, S | 1 |
| Atilla, S | 1 |
| Ataoglu , O | 1 |
| Isik, S | 1 |
| Ohnishi, T | 1 |
| Ikemoto, I | 1 |
| Ohishi, Y | 1 |
| Yamazaki, H | 1 |
| Horiuchi, K | 1 |
| Tsuboi, N | 1 |
| Yoshida, K | 1 |
| Akimoto, M | 1 |
| Souverein, PC | 1 |
| Herings, RM | 1 |
| Man in 't Veld, AJ | 1 |
| Leufkens, HG | 1 |
| Mosli, HA | 1 |
| Atwa, MA | 1 |
| Mahassini, SH | 1 |
| Chrischilles, E | 1 |
| Rubenstein, L | 1 |
| Chao, J | 1 |
| Gilden, D | 1 |
| Shah, H | 1 |
| Keledjian, K | 1 |
| Kim, G | 1 |
| Doruk, E | 1 |
| Boyle, P | 1 |
| Robertson, C | 1 |
| Manski, R | 1 |
| Akduman, B | 1 |
| Kortmann, BB | 1 |
| Rossi, C | 1 |
| Sonke, GS | 1 |
| Floratos, DL | 1 |
| Kiemeney, LA | 1 |
| Miekos, E | 1 |
| Trzepizur, Z | 1 |
| Rózanski, W | 1 |
| Boniecki, R | 1 |
| Kusnierz, J | 1 |
| Jablonowski, Z | 1 |
| Zydek, C | 1 |
| Tanaka, Y | 1 |
| Masumori, N | 1 |
| Itoh, N | 1 |
| Sato, Y | 1 |
| Takahashi, A | 1 |
| Ogura, H | 1 |
| Furuya, S | 1 |
| Tsukamoto, T | 1 |
| Puras-Baez, A | 1 |
| Soloway, M | 1 |
| Lowe, F | 1 |
| Moon, T | 1 |
| Leifer, G | 1 |
| Madsen, P | 1 |
| Shapiro, E | 3 |
| Hartanto, V | 1 |
| Fabricius, PG | 2 |
| Hannaford, JM | 2 |
| Lloyd, SN | 1 |
| Buckley, JF | 1 |
| Chilton, CP | 1 |
| Ibrahim, I | 1 |
| Kaisary, AV | 1 |
| Laddu, A | 2 |
| Di Silverio, F | 1 |
| Heinzl, S | 1 |
| Machi, G | 1 |
| Morita, T | 2 |
| Kondo, S | 1 |
| Meretyk, S | 1 |
| Knapp-Maloney, G | 3 |
| Soloway, MS | 1 |
| Rangel, MC | 1 |
| Park, YC | 1 |
| Nishioka, T | 1 |
| Arai, Y | 1 |
| Tomoyoshi, T | 1 |
| Hayashida, H | 1 |
| Nagai, N | 1 |
| Inoue, H | 1 |
| Kataoka, K | 1 |
| Kitagawa, Y | 1 |
| Woods, AL | 1 |
| Weizert, P | 1 |
| Dunzendorfer, U | 3 |
| Maurath, C | 1 |
| Sunshine, H | 1 |
| Henry, D | 1 |
| Laddu, AR | 1 |
| Baumann, M | 2 |
| Gup, DI | 1 |
| Wozniak-Petrofsky, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT03314025] | Phase 2 | 158 participants (Anticipated) | Interventional | 2017-10-06 | Recruiting | ||
| The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
| Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of Org 3236 Tablets in Men With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia (BPH)[NCT00651807] | Phase 2 | 16 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Business Reasons) | ||
| Medical Therapy of Prostatic Symptoms[NCT00021814] | Phase 3 | 3,407 participants (Actual) | Interventional | 1995-12-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH[NCT01736033] | Phase 4 | 545 participants (Actual) | Interventional | 2012-02-29 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
43 reviews available for terazosin and Adenoma, Prostatic
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlle | 1997 |
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
Topics: Adrenergic alpha-Antagonists; Dizziness; Doxazosin; Humans; Hypotension; Lower Urinary Tract Symptom | 2016 |
[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Evidence-Based Medicine; Humans; Male; Prazosin; Prostatic | 2008 |
Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia; Randomized Controlled T | 2009 |
[How effective is finasteride?].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Comb | 2011 |
Terazosin for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Antineoplastic Agents; Humans; Male; Middle Aged; Prazosin; Pros | 2002 |
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostate; Prostatic Hype | 2003 |
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug The | 2003 |
[Pharmacologic treatment of benign prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasterid | 2003 |
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; | 2004 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Co | 2006 |
[Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Huma | 2007 |
FPIN's clinical inquiries. Medical treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Antineoplastic Agents; Enzyme | 2008 |
[Terazosine in the treatment of benign prostatic hypertrophy].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Drug Therapy, Combination; Flutamide; Humans; Ma | 1993 |
[Therapy of benign prostatic hyperplasia with alpha receptor blockers].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Receptors, A | 1995 |
Therapeutic controversies: clinical treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Cholestenone 5 alpha-Reductase; Clinical Trials as Topic; Drug Therapy | 1995 |
[New in Austria approved specialty drugs and new knowledge regarding currently available specialty drugs. Uroflo].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Dose-Response Relationship, D | 1995 |
The role of alpha 1-blockade in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aging; Clinical Trials as Topic; Humans; Male; Phenoxybenzamine; Prazo | 1993 |
Medical therapy for benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androgen Antagonists; Anilides; Clinical | 1993 |
Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Doxazosin; Half-Life; Humans | 1996 |
Measures of Proscar, Hytrin, and Cardura side effects.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia | 1997 |
Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.
Topics: Adrenergic alpha-Antagonists; Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Pract | 1997 |
Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Clinical Trials as Topic; Dizziness; Humans; | 1997 |
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prosta | 1997 |
[Terazosin].
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia | 1998 |
Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Hormones; Humans; Male; Patient S | 1998 |
Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Aged; Female; Humans; Hypertension; Male; Multicenter Studies as Topic | 1998 |
Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Male; Prazosin; Prostatic | 1998 |
Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia | 1997 |
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizzines | 1999 |
Medical therapy for benign prostatic hyperplasia: a review of the literature.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic H | 2000 |
Development of a new in vitro model for the study of benign prostatic hyperplasia.
Topics: Cell Differentiation; Coculture Techniques; Epithelial Cells; Humans; Male; Microscopy, Electron; Mo | 2000 |
Clinical perspective on apoptosis in the management of the BPH patient.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Humans; Male; Musc | 2000 |
[Drugs for the treatment of benign prostatic hypertrophy].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; D | 2000 |
Benign prostatic hyperplasia. The Saudi perspective in the year 2000.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Age Distribution; Age of Onset; Aged; Fi | 2000 |
Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Bayes Theorem; Humans; Male; Middle Aged; Prazosin; Prostatic Hy | 2001 |
Terazosin, doxazosin, and prazosin: current clinical experience.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prostatic | 2001 |
5alpha-reductase inhibitors: what role should they play?
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Therapy, C | 2001 |
Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; T | 2000 |
Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Male; Prazosin; Prostatic Hyperplasi | 1992 |
[Prostatic adenoma: new drugs, new surgical techniques].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androstenes; Azasteroids; Cystoscopes; D | 1992 |
Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Brimonidine Tartrate; Carbachol; Humans; Ma | 1990 |
The efficacy and safety of terazosin for the treatment of symptomatic BPH.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Humans; Male; Middle Aged; Or | 1991 |
66 trials available for terazosin and Adenoma, Prostatic
| Article | Year |
|---|---|
A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Antihypertensive Agents; Carvedilol; Cross-Over Studi | 2021 |
Comparison of Anti BPH capsule (herbal) and Terazosin HCl in the treatment of benign prostate hyperplasia.
Topics: Adult; Aged; Aged, 80 and over; Capsules; Humans; Male; Middle Aged; Plant Extracts; Plant Preparati | 2017 |
[Efficacy and safety of Tonglin Powder in the treatment of benign prostatic hyperplasia].
Topics: Adult; Aged; Aged, 80 and over; Drugs, Chinese Herbal; Humans; Male; Middle Aged; Prazosin; Prostati | 2016 |
Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Doxazos | 2013 |
[Peculiarities of clinical course, diagnostics and treatment of overactive bladder in men older than 60 years].
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Prazosin; Prostatic H | 2014 |
[Efficacy of electroacupuncture in treating 93 patients with benign prostatic hyperplasia].
Topics: Aged; Aged, 80 and over; Electroacupuncture; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperpla | 2008 |
[Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug T | 2009 |
Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches.
Topics: Aged; Antineoplastic Agents; Humans; Logistic Models; Male; Medicine; Medicine, Chinese Traditional; | 2010 |
Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Human | 2003 |
Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Hypertension; Male; Prazosin; Prostatic | 2003 |
Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
Topics: Clinical Trials as Topic; Doxazosin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Com | 2004 |
Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Doxazosin; Humans; Male; Middle Aged; Prazos | 2004 |
Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Phytotherapy; Plants, Medicinal; Praz | 2005 |
Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzhydryl Compounds; Cresols; Drug Therapy, Combination; Humans | 2007 |
Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Over Studies; Dizziness; Drugs, Generic; Edema; | 2007 |
[Comparison of different drugs on the treatment of benign prostate hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; | 2007 |
Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prostatic Hy | 1993 |
Use of terazosin in prostatodynia and validation of a symptom score questionnaire.
Topics: Adrenergic alpha-Antagonists; Adult; Humans; Logistic Models; Male; Middle Aged; Pain; Pain Measurem | 1994 |
Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind M | 1994 |
Terazosin in the treatment of hypertension and symptomatic benign prostatic hyperplasia: a primary care trial.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Middle Aged; Prazosin; Primary Health Care | 1994 |
Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Follow-Up Studies; Humans; Male; Prazosin; Prostatic H | 1995 |
Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Decision Trees; Enzyme Inhibitors; Finasteride; Health Care Cost | 1995 |
Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Doxazosin; Drug Administration Schedule; Humans; | 1995 |
The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Humans; Male; Middle Ag | 1996 |
The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Cost-Benefit Analysis; | 1996 |
Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urin | 1996 |
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Canada; Double-Blind Me | 1996 |
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combinatio | 1996 |
The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Mid | 1996 |
Terazosin vs finasteride for BPH.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Combinations; Enzyme Inhibitors; Finaste | 1996 |
Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prospect | 1997 |
Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prosta | 1997 |
Influence of prostate size on terazosin efficacy.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prosta | 1997 |
Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Longitudinal Stu | 1997 |
Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Dose-Response Relationship, D | 1997 |
[Therapy of benign prostatic hyperplasia: terazosin or finasteride?].
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Pra | 1997 |
A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Blood Pressure; Blood Pressure Moni | 1998 |
The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combinatio | 1998 |
Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressur | 1998 |
Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Diathermy; Humans; Male; Microwaves; Middle Aged; Prazosin; Pros | 1999 |
Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Finas | 1999 |
Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Hypertension; Male; Prazosin; Prostatic | 1999 |
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Dose-Response Relations | 1998 |
[Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy].
Topics: Aged; Coronary Disease; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Prazosin; Prostatic Hype | 1999 |
The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia | 2000 |
A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prazosi | 2000 |
Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Prazosin; Prostatic Hyperplasia; S | 2000 |
[Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Ambulatory Care; Double-Blind Method; Humans; | 2000 |
[Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination].
Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Humans; Male; Practice Patterns, Physicians'; P | 2000 |
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Follow-Up Studies; Hum | 2001 |
[The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prazos | 2001 |
[A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Prazosi | 2001 |
The efficacy of terazosin for treating benign prostatic hyperplasia: a multicentre clinical trial.
Topics: Adrenergic alpha-Antagonists; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prazosin; | 2002 |
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; | 1992 |
Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Follow-Up Studies; Human | 1992 |
Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial.
Topics: Adrenergic alpha-Antagonists; Aged; Clinical Protocols; Double-Blind Method; Humans; Male; Middle Ag | 1992 |
Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Male; Prazosin; Prostatic Hyperplasi | 1992 |
Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy.
Topics: Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Middle Aged; Prazosin; Prosta | 1992 |
The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Patient Compliance | 1992 |
Efficacy of terazosin in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Drug Evaluation; Humans; Male; Pra | 1992 |
[A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M | 1992 |
Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Humans; Male; Middle Age | 1990 |
A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Drug Administration Schedule; Humans; Male; Midd | 1990 |
The efficacy and safety of terazosin for the treatment of symptomatic BPH.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Humans; Male; Middle Aged; Or | 1991 |
Clinical experience: symptomatic management of BPH with terazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Multicenter Studies as Topic; Placebos; Prazosin; | 1988 |
Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Muscl | 1988 |
Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Muscl | 1988 |
Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Muscl | 1988 |
Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Multicenter Studies as Topic; Muscl | 1988 |
84 other studies available for terazosin and Adenoma, Prostatic
| Article | Year |
|---|---|
N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Amid | 1997 |
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dogs; Humans; Indole | 1997 |
Identification of a dihydropyridine as a potent alpha1a adrenoceptor-selective antagonist that inhibits phenylephrine-induced contraction of the human prostate.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Animals; Brain; Ca | 1998 |
Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cell Line; Dogs; Heterocyclic Compounds, 3-Ri | 2000 |
In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Animals; Biological Availability; Caco-2 Cells; Crystallography, X-Ray | 2000 |
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Dogs; Dox | 2001 |
Effect of Terazosin Hydrochloride Combined with Interventional Embolisation on Prostate Volume and Quality of Life of Elderly Patients with Prostatic Hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Embolization, Therapeutic; Humans; Male; Prostate; Prostate-Spec | 2023 |
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Midd | 2019 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug | 2015 |
Assessment of Urologists' Knowledge of Intraoperative Floppy Iris Syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Competence; Fellowships and Scholarships; Female; | 2016 |
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosi | 2008 |
Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Logistic Models; Male; Middle Aged; P | 2008 |
A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results.
Topics: Acetamides; Adrenergic alpha-Antagonists; Aged; Behavior Therapy; Benzhydryl Compounds; Combined Mod | 2009 |
Iris morphologic changes related to alpha(1)-adrenergic receptor antagonists implications for intraoperative floppy iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cross-Sectional Studies | 2009 |
Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: focus on detrusor overactivity.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Animals; Calcium Channel Blockers; Drug Therapy, Combinati | 2009 |
Development and validation of an Arabic version of the International Prostate Symptom Score.
Topics: Adrenergic alpha-Antagonists; Humans; Language; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; | 2010 |
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Redu | 2010 |
Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Coagulation; Blood Pressure; Brachial Artery; Doxazosin; E | 2011 |
Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combinati | 2012 |
Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combine | 2002 |
Effect of terazosin on clinical benign prostatic hyperplasia in older adults.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Urin | 2003 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietar | 2004 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Dr | 2004 |
[Effect of nitric oxide donor and alpha1-receptor antagonist on proliferation/apoptosis of hyperplastic prostatic stromal cells in vitro].
Topics: Adrenergic alpha-Antagonists; Apoptosis; Dose-Response Relationship, Drug; Drug Synergism; Humans; I | 2004 |
Meta-analysis: creating a level playing field for the patient with symptomatic benign prostatic hyperplasia?
Topics: Antineoplastic Agents; Catheter Ablation; Finasteride; Humans; Male; Meta-Analysis as Topic; Prazosi | 2004 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; | 2004 |
Baroreceptor mediated blood pressure regulation is not affected during dose dependent inhibition of prostatic contractions by terazosin.
Topics: Animals; Baroreflex; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Male; Muscle Contractio | 2004 |
alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Pra | 2006 |
Significance of nocturnal hesitancy in treatment of men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Polyuria; Prazosin; Prospective Studies; Prostatic Hyper | 2006 |
Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Topics: Adrenergic alpha-Antagonists; Aged; Bangladesh; Enzyme Inhibitors; Finasteride; Humans; Male; Middle | 2005 |
Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Pra | 2007 |
Lichenoid drug eruption to terazosin.
Topics: Adrenergic alpha-Antagonists; Aged, 80 and over; Drug Eruptions; Humans; Lichenoid Eruptions; Male; | 2008 |
Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prazosin; Prostate | 2008 |
Acute intoxication with terazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Bradycardia; Drug Overdose; Electrocardiography; Humans; Male; P | 2008 |
Terazosin for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Hypotension, Orthostatic; Male; Prazosin; Prostatic Hyperplasi | 1994 |
Men's health issues.
Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic | 1993 |
Terazosin now indicated for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia | 1994 |
Effect of terazosin on urine storage and voiding in the aging male with prostatism.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Prazosin; Prosta | 1994 |
[Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
Topics: Adrenergic alpha-Antagonists; Aged; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostati | 1994 |
Terazosin for BPH.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Humans; Hypertension; Male; Prazosin; Prosta | 1995 |
[Terazosin in the treatment of benign prostatic hypertrophy].
Topics: Adrenergic alpha-Antagonists; Humans; Male; Multicenter Studies as Topic; Prazosin; Prostatic Hyperp | 1995 |
Hytrin treatment of hypertension and benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prazosin; Prostatic Hyperplasia | 1995 |
The medication minute: terazosin.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Patient Education as Topic; Prazosin; Prostatic Hyperpla | 1995 |
Combination drug therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Drug Synergism; Drug Therapy, Combination; Finasteride; Humans; Male; | 1995 |
Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate.
Topics: Adrenergic alpha-Antagonists; Animals; Dogs; Dose-Response Relationship, Drug; Epinephrine; Male; Mu | 1993 |
Transurethral resection of the prostate: still the gold standard?
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Androstenes; Azasteroids; C | 1993 |
[Pharma-clinics. Drug of the month. Terazosine (Hytrin)].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Hypertension; Male; Middle Aged; Praz | 1995 |
Treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Mal | 1996 |
Study provides head-to-head comparison of terazosin, finasteride.
Topics: Adrenergic alpha-Antagonists; Cholestenone 5 alpha-Reductase; Drug Therapy, Combination; Finasteride | 1996 |
Terazosin, finasteride, or both in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prazosin; Prostatic Hyperplasia; Urodynamics | 1997 |
Terazosin, finasteride, or both in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hypotensio | 1997 |
Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Doxazosin; Male; Prazosin; Prostatic Hy | 1996 |
[Ureteral jet in patients with benign prostatic hypertrophy: prognostic evaluation during single and combined therapy].
Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Mal | 1996 |
What is the best medical treatment for benign prostate hyperplasia?
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Therapy, C | 1997 |
Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Laser Therapy; Male; Microwaves; Middle Aged; Prazosin; | 1997 |
Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals | 1997 |
Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Enzyme Inhibitors; Finasteri | 1997 |
The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Doxazosin; Humans; Male; Praz | 1997 |
Severe cutaneous reaction due to terazosin.
Topics: Adrenergic alpha-Antagonists; Drug Eruptions; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperpl | 1998 |
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Doxazosin; Humans; | 1999 |
Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study.
Topics: Adrenergic alpha-Antagonists; Aged; Decision Trees; Enzyme Inhibitors; Finasteride; Humans; Male; Mi | 1999 |
By the way, doctor... I'm 78 and have more and more difficulty urinating. I get up three times a night - sometimes more - to go to the bathroom and it takes me a while to start urinating and even longer to stop. I know that this is probably a prostate pro
Topics: Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulf | 1999 |
Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Drug Prescriptions; Humans; | 1999 |
Diet and herbs for BPH?
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Phytoth | 2000 |
Does induction of apoptosis contribute to the overall clinical profile of terazosin? Introduction.
Topics: Apoptosis; Cell Division; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Stromal Cells | 2000 |
Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Biopsy; Cell Divis | 2000 |
Transurethral resection of the prostate: failure patterns and surgical outcomes in patients with symptoms refractory to alpha-antagonists.
Topics: Adrenergic alpha-Antagonists; Aged; Comorbidity; Doxazosin; Humans; Louisiana; Male; Postoperative C | 2000 |
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Antibodies, Monoclonal; Apoptosis; Cell Division; Drug Combinations; E | 2001 |
Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Biopsy; Humans; Magnetic Resonance Imaging; M | 2001 |
The short-term effects of terazosin in Japanese men with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M | 2001 |
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Bias; Cardiovascular Diseas | 2001 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comor | 2001 |
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Endothelial Growth | 2001 |
Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Cholesterol; Humans; Lipoproteins; Male; Middle Aged; Pra | 2001 |
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
Topics: Adrenergic beta-Antagonists; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyper | 2002 |
Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Japan; Male; Middle Aged; Muscle Cont | 2002 |
The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Muscle, Smooth; Prazosin; Prostatic H | 1992 |
The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Flutamide; Humans; Male; Middle Aged; | 1992 |
[Comparison of selective alpha-1 blockades for alpha-receptors in human hypertrophied prostatic adenomas].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Piperazines; Prazosin; Prostatic Hyperpla | 1992 |
The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Florida; Follow-Up Studies; Hospit | 1992 |
[Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity].
Topics: Adenoma; Adrenergic alpha-Antagonists; Aged; Humans; Male; Muscle Contraction; Muscle, Smooth; Norep | 1991 |
The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain.
Topics: Adrenergic alpha-Antagonists; Aged; Animals; Binding Sites; Binding, Competitive; Cerebral Cortex; D | 1988 |
The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Humans; Male; Middle Aged; Prazosin; Prostatic H | 1989 |
Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Pilot Projects; Pr | 1989 |